NCT00603993View on ClinicalTrials.gov

Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL

Enrollment

88

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

November 30, 2006

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

Adalimumab

40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection

Trial Locations (16)

Unknown

Aichi

Chiba

Fukuoka

Gunma

Hokkaido

Hyōgo

Ibaraki

Kanagawa

Miyagi

Nagano

Okayama

Osaka

Saitama

Shizuoka

Tokyo

Toyama

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Abbott Japan Co.,Ltd

INDUSTRY

collaborator

Eisai Co., Ltd.

INDUSTRY

lead

Abbott

INDUSTRY